You can buy or sell MorphoSys and other stocks, options, ETFs, and crypto commission-free!
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. Read More The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Planegg, Bayern (Bavaria)
52 Week High
52 Week Low
Research And Development
Seeking AlphaMay 16
Morphosys' lead drug successful in mid-stage DLBCL study
Morphosys AG (NASDAQ:MOR) announces the successful outcome of a Phase 2 clinical trial, L-MIND, evaluating lead candidate MOR208, combined with Celgene's (NASDAQ:CELG) Revlimid (lenalidomide), in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are ineligible for high-dose chemotherapy and autologous stem cell transplantation.
Seeking AlphaMay 12
MorphoSys AG CEO Simon Moroney on Q1 2019 Results - Earnings Call Transcript
MorphoSys AG (OTCPK:MPSYF) Q1 2019 Earnings Conference Call May 8, 2019 8:00 AM ET Company Participants Sarah Fakih - Head of Corporate Communications and IR Simon Moroney - CEO Jens Holstein - CFO Conference Call Participants James Gordon - JPMorgan Danielle Brill - Piper Jaffray Shanshan Xu - Berenberg Capital Partners Gunnar Romer - Deutsche Bank Graig Suvannavejh - Goldman Sachs Gary Waanders - Bryan Garnier & Co. Zoe Karamanoli - RBC Victoria English - Evernow Publishing Steve McGarry - H...
Markets InsiderMay 9
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
DGAP Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 09.05.2019 / 17:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: MorphoSys AG Street: Semmelweisstr. 7 Postal code: 82152 Ci...
Available Aug 6, After Hours